{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:27:18Z","timestamp":1787765238823,"version":"build-2784847793"},"reference-count":22,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2020,10]]},"abstract":"\n Background:<\/jats:title>\n \n This work aimed to evaluate the influence of two chelators: DOTA(SCN) and DOTA(NHS) on radioimmunotherapy using\n 177<\/jats:sup>\n Lu-DOTA-Rituximab preparations in murine lymphoma xenograft models. Subsequently, based on animal data, the organ radiation-absorbed doses were extrapolated to humans (adult male).\n <\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n \n Therapeutic efficacy of\n 177<\/jats:sup>\n Lu-DOTA-Rituximab was evaluated in male nude mice bearing either Raji (B lymphocyte, CD20\n +<\/jats:sup>\n ) and Jurkat (T lymphocyte, CD20) xenografts, utilizing an anti-CD20 antibody\u2014Rituximab conjugate with either DOTA(SCN) or DOTA(NHS). The DOTA-Rituximab conjugates were prepared in the form of freeze-dried kits.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n All radioimmunoconjugates were obtained with high radiolabeling yield (radiochemical purity, RCP\u2009>\u200995%) and specific activity of ca. 0.5 GBq\/mg. Therapeutic effects of\n 177<\/jats:sup>\n Lu-DOTA-Rituximab were observed in animals regardless whether DOTA(SCN) or DOTA(NHS) were used for conjugation. Importantly, therapy involving\n 177<\/jats:sup>\n Lu-DOTA-Rituximab was more effective than use of Rituximab alone.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n \n The degree of antitumor efficacy was dependent on the type of applied bifunctional chelators conjugated to mAb. However, this difference was not statistically significant. Dosimetry calculations showed that the absorbed radiation doses extrapolated to humans were very low for osteogenic cells regardless of the conjugates. Organs like the liver and spleen, treated with\n 177<\/jats:sup>\n Lu-DOTA(SCN)-Rituximab, showed similar radiation absorbed doses when compared with\n 177<\/jats:sup>\n Lu-DOTA(NHS)-Rituximab.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1089\/cbr.2019.3405","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T17:53:42Z","timestamp":1586282022000},"page":"558-562","source":"Crossref","is-referenced-by-count":7,"title":["Impact of DOTA-Chelators on the Antitumor Activity of\n 177<\/sup>\n Lu-DOTA-Rituximab Preparations in Lymphoma Tumor-Bearing Mice"],"prefix":"10.1177","volume":"35","author":[{"given":"Wioletta","family":"Wojdowska","sequence":"first","affiliation":[{"name":"National Centre for Nuclear Research, Radioisotope Centre POLATOM, Research and Development Department, Otwock, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Karczmarczyk","sequence":"additional","affiliation":[{"name":"National Centre for Nuclear Research, Radioisotope Centre POLATOM, Research and Development Department, Otwock, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Balog","sequence":"additional","affiliation":[{"name":"Gamma-VET Ltd, Budapest, Hungary."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Sawicka","sequence":"additional","affiliation":[{"name":"National Centre for Nuclear Research, Radioisotope Centre POLATOM, Research and Development Department, Otwock, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zita","family":"P\u00f6st\u00e9nyi","sequence":"additional","affiliation":[{"name":"Synlab Budapest Diagnostic Center, Microbiology Laboratory Synlab Hungary Ltd, Budapest, Hungary."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Kov\u00e1cs-Ha\u00e1sz","sequence":"additional","affiliation":[{"name":"National Public Health Center, National Research Directorate on Radiobiology and Radiohygiene, Budapest, Hungary."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Poly\u00e1k","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Laszuk","sequence":"additional","affiliation":[{"name":"National Centre for Nuclear Research, Radioisotope Centre POLATOM, Research and Development Department, Otwock, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Miko\u0142ajczak","sequence":"additional","affiliation":[{"name":"National Centre for Nuclear Research, Radioisotope Centre POLATOM, Research and Development Department, Otwock, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Garnuszek","sequence":"additional","affiliation":[{"name":"National Centre for Nuclear Research, Radioisotope Centre POLATOM, Research and Development Department, Otwock, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"e_1_3_4_2_2","first-page":"3304","article-title":"Low versus high-dose radioimmunotherapy with humanized anti-CD20 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies","volume":"5","author":"Behr TM","year":"1999","unstructured":"Behr TM, , Wormann B, , Gramatzki M, et al. Low versus high-dose radioimmunotherapy with humanized anti-CD20 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res, 1999; 5:3304.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-011-0527-x"},{"key":"e_1_3_4_4_2","first-page":"1201","article-title":"Influence of DOTA chelators on radiochemical purity and biodistribution of 177Lu- and 90Y-Rituximab in Xenografted Mice","volume":"17","author":"Karczmarczyk U","year":"2018","unstructured":"Karczmarczyk U, , Wojdowska W, , Miko\u0142ajczak R, et al. Influence of DOTA chelators on radiochemical purity and biodistribution of 177Lu- and 90Y-Rituximab in Xenografted Mice. Iran J Pharm Res, 2018; 17:1201.","journal-title":"Iran J Pharm Res"},{"key":"e_1_3_4_5_2","first-page":"457","article-title":"Yttrium-90 labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma","volume":"2","author":"Knox SJ","year":"1996","unstructured":"Knox SJ, , Goris ML, , Trisler K, et al. Yttrium-90 labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res, 1996; 2:457.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/2008-2231-22-58"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.115170"},{"key":"e_1_3_4_8_2","first-page":"156","article-title":"The use of monoclonal antibody in treatment of indolent non-Hodgkin's lymphoma","volume":"5","author":"Boguradzki P","year":"2001","unstructured":"Boguradzki P, The use of monoclonal antibody in treatment of indolent non-Hodgkin's lymphoma. Contemp Oncol, 2001; 5:156.","journal-title":"Contemp Oncol"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874471011306020001"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874471006666131119212015"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2005.02.006"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0756"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200115020-00001"},{"key":"e_1_3_4_15_2","first-page":"173","article-title":"Rituximab in haematology and oncology in 10 years of experience","volume":"12","author":"Wache A","year":"2008","unstructured":"Wache A, , Gil L, , Komarnicki M. Rituximab in haematology and oncology in 10 years of experience. Contemp Oncol, 2008; 12:173.","journal-title":"Contemp Oncol"},{"key":"e_1_3_4_16_2","first-page":"335","article-title":"Molecular mechanisms of the therapeutic activity of Rituximab. The monoclonal antibody against CD20 antigen","volume":"34","author":"Bil J","year":"2007","unstructured":"Bil J, , Winiarska M. Molecular mechanisms of the therapeutic activity of Rituximab. The monoclonal antibody against CD20 antigen. Adv Cell Biol, 2007; 34:335.","journal-title":"Adv Cell Biol"},{"key":"e_1_3_4_17_2","first-page":"327","article-title":"Optimization of radioimmunotherapy of renal cell carcinoma: Labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu or 186Re","volume":"45","author":"Brouwers AH","year":"2004","unstructured":"Brouwers AH, , van Eerd JEM, , Frielink C, et al. Optimization of radioimmunotherapy of renal cell carcinoma: Labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu or 186Re. J Nucl Med, 2004; 45:327.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_18_2","first-page":"1697","article-title":"The humpral immune response to macrocyclic chelating agent DOTA depends on the carrier molecule","volume":"42","author":"Perico ME","year":"2001","unstructured":"Perico ME, , Chinol M, , Nacca A, et al. The humpral immune response to macrocyclic chelating agent DOTA depends on the carrier molecule. J Nucl Med, 2001; 42:1697.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874471008666141215151253"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00300234"},{"key":"e_1_3_4_21_2","unstructured":"Radiation dose assessment resource (RADAR)\u2014Available phantoms. Online document at www.doseinfo-radar.com\/RADARphan.html Accessed November7 2019."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.4103\/0971-6203.103609"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874471008666150313103849"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2019.3405","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2019.3405","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2019.3405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:15:35Z","timestamp":1777385735000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2019.3405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1089\/cbr.2019.3405"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2019.3405","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}